Roche made over 100 times the cost of a medicine that it sold in India, calculations show; company defends itself

A recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal muscular atrophy (SMA), potentially earning 115 times its clinical trial expenses. Knowledge Ecology International estimates trial costs at $50 million, while Roche's risdiplam revenue reached $5.8 billion. Roche defends its pricing, citing unsuccessful projects and ongoing research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8n9koNR
via IFTTT